Great expectations—Isconova to receive the 2010 Bona Postulata Prize
Friday, February 12th, 2010
Isconova has been awarded the 2010 Bona Postulata Prize, for being a growing company with a great potential to become even more successful. The Bona Postulata Prize [1] is not intended to be a reward for what the company has accomplished so far—it is awarded based on the company’s imminent opportunities and existing potential. The founders are 15 well known companies and organizations with the purpose to help local companies getting attention, support and media exposure. Bona postulata is Latin for great expectations.
Lena Söderström, CEO of Isconova commented: “The prize is an appreciated recognition and an inspiration to us in our efforts to establish Isconova as a leading provider of vaccine adjuvants”
About Isconova AB
Isconova AB develops, manufactures, out-licenses and sells state-of-the art adjuvants for the creation of highly effective antigen delivery systems for vaccine development, antibody production and immune response studies. In addition, the company sells reagents for formulating custom made complexes for the end-user. The products are based on the proprietary ISCOM technology platform and the market is global. Isconova was founded in 2000 as a spin-off from the Swedish University of Agricultural Science in Uppsala to further develop the ISCOM technology and make it commercially available and accessible.
For more information, visit Isconova’s website: www.isconova.se
Contact
Isconova AB, Uppsala, Sweden
Lena Söderström, CEO
Phone: +46 18 57 24 00
E-mail: lena.soderstrom@isconova.se
Next step: ask a question/request support